Released Feb 28, 2013, after the close
10-K filed Feb 28, 2013, 59 days after period end · 0001144204-13-012065
Q4 2012 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.17M$1.17M derived−50.4% vs Q4 2011−68.5% vs Q3 2012
Net Income-$9.88M-$9.88M derivedN/M vs Q4 2011N/M vs Q3 2012
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived-$1,130,000N/M
Operating Incomederived-$10,167,000N/M
Operating Cash Flowderived$1,821,000N/M
Free Cash Flowderived$1,570,000N/M
Margins · derived
Gross margin-96.4%−108.9 pt vs Q4 2011
Operating margin-867.5%−492.5 pt vs Q4 2011
Net margin-842.7%−465.4 pt vs Q4 2011
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2012dderived from reported figures | Q4 2011dderived from reported figures | Q4 2010dderived from reported figures |
|---|---|---|---|
| Revenue | $1.17M | $2.36M | — |
| Net Income | -$9.88M | -$8.91M | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR